SCHEMBL4904489

SCHEMBL4904489

CC(C)NS(=O)(=O)c1ccc2c(c1)C(=NNc1cccc(C(=O)NCc3ccccc3)c1)C(=O)N2

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TP53 P04637 1/20 0.45
TSHR P16473 1/20 0.45
HTT P42858 1/20 0.44
ALDH1A1 P00352 2/20 0.43
HSD17B10 Q99714 2/20 0.43
GAA P10253 1/20 0.43
PTPN11 Q06124 1/20 0.42
KDM4E B2RXH2 1/20 0.42
ADAMTS4 O75173 1/20 0.41
LMNA P02545 2/20 0.40
HDAC8 Q9BY41 2/20 0.40
HDAC6 Q9UBN7 2/20 0.40
MEN1 O00255 2/20 0.40
KMT2A Q03164 2/20 0.40
RAB9A P51151 1/20 0.40
POLB P06746 3/20 0.40
MAPT P10636 3/20 0.39
MAPK1 P28482 1/20 0.39
HSP90AA1 P07900 1/20 0.38
VCP P55072 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4904487 1.00 TP53 (0.45) TP53TSHRHTTALDH1A1HSD17B10
SCHEMBL4896236 0.91 PTPN11 (0.53) TSHRHTTALDH1A1PTPN11LMNA
SCHEMBL4896246 0.91 PTPN11 (0.53) TSHRHTTALDH1A1PTPN11LMNA
SCHEMBL4903245 0.90 HTR2B (0.39) TP53TSHRALDH1A1GAAPTPN11
SCHEMBL4903236 0.90 HTR2B (0.39) TP53TSHRALDH1A1GAAPTPN11
SCHEMBL4897722 0.88 POLB (0.47) GAAPTPN11KDM4EMEN1KMT2A
SCHEMBL4897715 0.88 POLB (0.47) GAAPTPN11KDM4EMEN1KMT2A
SCHEMBL5322045 0.88 PTPN11 (0.52) HTTALDH1A1HSD17B10GAAPTPN11
SCHEMBL14111860 0.88 PTPN11 (0.52) HTTALDH1A1HSD17B10GAAPTPN11
SCHEMBL4900110 0.87 HTR2B (0.41) HTTALDH1A1GAAPTPN11HDAC8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8987474-B2 Inhibition of Shp2/PTPN11 protein tyrosine phosphatase by NSC-87877, NSC-117199 and their analogs UNIVERSITY OF SOUTH FLORIDA (US) 2015-03-24 US disclosed
US-20080176309-A1 8-hydroxy-7-(6-sulfonaphthalen-2-yl)diazenyl-quinoline-5-sulfonic acid (NSC-87877); Src homology-2 domains; Noonan syndrome, cancer UNIVERSITY OF SOUTH FLORIDA (US) 2008-07-24 US disclosed
WO-2007117699-A2 INHIBITION OF SHP2/PTPN11 PROTEIN TYROSINE PHOSPHATASE BY NSC-87877, NSC-117199 AND THEIR ANALOGS UNIVERSITY OF SOUTH FLORIDA (US) 2007-10-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080176309-A1 8-hydroxy-7-(6-sulfonaphthalen-2-yl)diazenyl-quinoline-5-sulfonic acid (NSC-87877); Src homology-2 domains; Noonan syndrome, cancer PTPN7, PTPN1, PTPN2 TP53 227/4885TSHR 1828/4885HTT 603/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.